Physician profile
Andrew Pellatt
NPI 1376031252
$2,963.84
in general payments reported to CMS, 2019-2025
15 companies · $1,787 in 2025
The $1,787 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $988 · 2024: $189 · 2025: $1,787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,663 · Food and Beverage: $920 · Education: $381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,662.50 |
| Food and Beverage | $920.11 |
| Education | $381.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,820.58 | 2024-2025 | |
| Lilly USA, LLC | $357.17 | 2023 | Jaypirca |
| E.R. Squibb & Sons, L.L.C. | $228.73 | 2023 | Reblozyl |
| Rigel Pharmaceuticals, INC. | $135.95 | 2023 | Tavalisse, Rezlidhia |
| Alexion Pharmaceuticals, INC. | $115.96 | 2023 | Ultomiris |
| Amgen INC. | $81.38 | 2024 | Vectibix |
| Pfizer INC. | $31.20 | 2023 | |
| Pharmacosmos Therapeutics INC. | $30.59 | 2023 | Monoferric |
| Janssen Biotech, INC. | $27.13 | 2023 | Talvey, Tecvayli, Darzalex |
| Merck Sharp & Dohme LLC | $27.10 | 2024 | Keytruda |
| Tempus Ai, INC | $24.78 | 2024 | Xt Cdx |
| Novartis Pharmaceuticals Corporation | $23.63 | 2023 | |
| Legend Biotech USA INC. | $22.36 | 2024 | |
| Incyte Corporation | $19.75 | 2023 | Jakafi |
| Pharmaessentia USA Corporation | $17.53 | 2023 | Besremi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Pellatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.